32.76
전일 마감가:
$32.35
열려 있는:
$32.45
하루 거래량:
341.84K
Relative Volume:
0.82
시가총액:
$897.37M
수익:
$86.93M
순이익/손실:
$-1.48M
주가수익비율:
-462.06
EPS:
-0.0709
순현금흐름:
$431.00K
1주 성능:
+5.85%
1개월 성능:
+8.26%
6개월 성능:
+107.08%
1년 성능:
+140.71%
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
명칭
Eton Pharmaceuticals Inc
전화
(847) 787-7361
주소
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ETON
Eton Pharmaceuticals Inc
|
32.76 | 880.66M | 86.93M | -1.48M | 431.00K | -0.0709 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 재확인 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | B. Riley Securities | Buy |
| 2025-01-06 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-04 | 재개 | H.C. Wainwright | Buy |
| 2024-05-06 | 개시 | Craig Hallum | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-01-04 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-20 | 개시 | B. Riley FBR | Buy |
| 2019-06-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Eton Pharmaceuticals (ETON) surges 19.8%: Is this an indication of further gains? - MSN
Eton Pharmaceuticals (ETON) Surges 4.75% as Momentum Builds Toward ResistanceWatchlist Stock Ideas - newsline.com
Trading the Move, Not the Narrative: (ETON) Edition - Stock Traders Daily
Eton Pharmaceuticals (NASDAQ: ETON) 2026 vote supports board and auditor - Stock Titan
Eton Pharmaceuticals (ETON) Gains 2.8% as Bullish Momentum Builds Toward ResistanceHigh Beta Stocks - newsline.com
Eton Pharmaceuticals Rallies as Stock Approaches Key Resistance (ETON)Total Put Call - newsline.com
Eton Pharmaceuticals (ETON) Holds Steady Near Resistance With Modest GainDividend ETF - newsline.com
ETON Q1 2026 Earnings: EPS Misses Estimates Despite Narrow ProfitCore Business Growth - newsline.com
Possible Bearish Signals With Eton Pharmaceuticals Insiders Disposing Stock - simplywall.st
ETON: Aggressively scaling rare disease portfolio with strong sales, margin growth, and patient focus - TradingView
[144] Eton Pharmaceuticals, Inc. SEC Filing - Stock Titan
Eton Pharmaceuticals (ETON) CFO reports 37,000 employee stock options - Stock Titan
Eton Pharmaceuticals CEO Sean Brynjelsen sells $3.83 million in stock - Investing.com India
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Scor - GuruFocus
Eton Pharmaceuticals CEO Sean Brynjelsen sells $3.83 million in stock By Investing.com - Investing.com South Africa
(ETON) Volatility Zones as Tactical Triggers - Stock Traders Daily
Eton Pharmaceuticals (ETON) CEO reports open-market sale of 120,000 shares - Stock Titan
120,000 ETON shares proposed for sale by affiliate (ETON) - Stock Titan
Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG - MarketBeat
Eton Pharmaceuticals Insider Sold Shares Worth $3,229,923, According to a Recent SEC Filing - Moomoo
Eton Pharmaceuticals CBO David Krempa sells $3.2m in stock By Investing.com - Investing.com Canada
Eton (ETON) CBO sells 100,000 shares after exercising 87,794 options - Stock Titan
Eton Pharmaceuticals (ETON) soars 6.7%: Is further upside left in the stock? - MSN
ETON SEC FilingsEton Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy - Insider Monkey
Eton Pharmaceuticals Inc (ETON) Shares Fall 6.9% -- GF Value Says Still Overvalued - GuruFocus
ETON (Nasdaq) Rule 144 shows RSUs and Options grants dated 2024–2026 - Stock Titan
5 Oversold Growth Stocks to Invest In Now - Insider Monkey
H.C. Wainwright reiterates Eton Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results By Investing.com - Investing.com Nigeria
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results - Investing.com
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug By Investing.com - Investing.com India
Eton Pharmaceuticals, Inc.Common Stock (NQ: ETON - The Chronicle-Journal
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug - Investing.com
Eton Pharmaceuticals Obtains US Commercialization Rights to Impavido - Moomoo
Eton (NASDAQ: ETON) licenses U.S. IMPAVIDO rights in rare disease push - Stock Titan
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) - The Manila Times
Eton Pharmaceuticals Announces U.S. Commercialization Rights for IMPAVIDO®, First FDA-Approved Oral Therapy for Leishmaniasis - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Price-Driven Insight from (ETON) for Rule-Based Strategy - Stock Traders Daily
H.C. Wainwright raises Eton Pharmaceuticals stock price target to $57 By Investing.com - Investing.com Canada
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2026 Earnings Call Transcript - Insider Monkey
Eton Pharmaceuticals Inc (ETON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eton Pharmaceuticals Inc 주식 (ETON) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BRYNJELSEN SEAN | President & CEO |
May 28 '26 |
Sale |
31.88 |
120,000 |
3,825,717 |
833,694 |
자본화:
|
볼륨(24시간):